Cargando…
Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
The treatment of myeloma has undergone extraordinary improvements in the past half century. These advances have been accompanied by a concern for secondary primary malignancies (SPMs). It has been known for decades that extended therapy with alkylating chemotherapy agents, such as melphalan, carries...
Autores principales: | Yang, Jay, Terebelo, Howard R., Zonder, Jeffrey A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407607/ https://www.ncbi.nlm.nih.gov/pubmed/22851973 http://dx.doi.org/10.1155/2012/801495 |
Ejemplares similares
-
The Nemesis of Specialism
Publicado: (1899) -
The Nemesis of Folly
Publicado: (1923) -
Nemesis of neglected neurosarcoidosis
por: Clifford, David B
Publicado: (2015) -
TAVR: nemesis of NOACs?
por: Polzin, Amin, et al.
Publicado: (2022) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani, Divaya, et al.
Publicado: (2017)